This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
BioMarin Pharmaceutical Bilan de santé
Santé financière contrôle des critères 5/6
BioMarin Pharmaceutical has a total shareholder equity of $4.9B and total debt of $1.1B, which brings its debt-to-equity ratio to 22.2%. Its total assets and total liabilities are $6.8B and $1.9B respectively. BioMarin Pharmaceutical's EBIT is $120.0M making its interest coverage ratio -3.5. It has cash and short-term investments of $1.1B.
Informations clés
22.2%
Ratio d'endettement
US$1.09b
Dette
| Ratio de couverture des intérêts | -3.5x |
| Argent liquide | US$1.13b |
| Fonds propres | US$4.90b |
| Total du passif | US$1.86b |
| Total des actifs | US$6.76b |
Mises à jour récentes de la santé financière
Pas de mise à jour
Recent updates
Analyse de la situation financière
Passif à court terme: BM8's short term assets ($3.0B) exceed its short term liabilities ($1.2B).
Passif à long terme: BM8's short term assets ($3.0B) exceed its long term liabilities ($698.0M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: BM8 has more cash than its total debt.
Réduire la dette: BM8's debt to equity ratio has reduced from 41.2% to 22.2% over the past 5 years.
Couverture de la dette: BM8's debt is not well covered by operating cash flow (12.8%).
Couverture des intérêts: BM8 earns more interest than it pays, so coverage of interest payments is not a concern.